PCSK9 inhibition with a novel fusion protein Oral PCSK9 inhibition: Clinical update VICTORION-INITIATE supports early inclisiran treatment in ASCVD LIBerate-HR: Lerodalcibep reduces LDL-C in high and very high risk CVD US patients missing out on bempedoic acid Evolocumab benefits in patients with autoimmune and inflammatory diseases

Børge Nordestgaard Articles

Is it time to upgrade Lp(a) to a therapeutic target in Guidelines?

Reports from the 10th Closed Expert Meeting of the PCSK9 Education and Research Forum Børge Nordestgaard

Posted on 17 July 2019 | Posted by Børge Nordestgaard | Posted in Webcasts, 10th Closed Scientific Expert Meeting of the Editorial Board

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters